AI Article Synopsis
- Rituximab has shown significant benefits for treating B-cell lymphoma and various autoimmune diseases, but its effects are limited in central nervous system (CNS) disorders due to the blood-brain barrier.
- Multiple sclerosis (MS), particularly its progressive phase, is a key CNS autoimmune disorder that resists existing treatments, highlighting the potential of intrathecal (IT) therapies to deliver drugs directly to the affected area.
- The review discusses findings from animal studies and human cases using intrathecal rituximab for CNS lymphomas and emphasizes the need for clinical trials on its use in multiple sclerosis, providing foundational data for future CNS autoimmune research.
Article Abstract
Rituximab has demonstrated a major effect in B-cell lymphoma and in a wide range of autoimmune disorders. Unfortunately, the blood-brain-barrier excludes the disorders restricted to the central nervous system (CNS) from the action of rituximab. The progressive phase of multiple sclerosis (MS) is a prototypical CNS autoimmune disorder characterized by an intrathecal compartmentalization of inflammation resisting all the available immunosuppressive treatments. As a consequence, intrathecal therapeutics are promising new approach in progressive MS. We first review data gathered from animal models and human off-label intrathecal rituximab use in CNS lymphomas, then summarize the recent evidence supporting the need for trials based on the intrathecal use of rituximab in multiple sclerosis. The experience obtained in these settings offers valuable preliminary data for future studies in CNS autoimmunity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/1389450115666141029234644 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A rapid progression from classical mantle cell lymphoma to a blastoid variant.
Leuk Res Rep
November 2024
Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Laboratoire d'hématologie biologique, Pierre-Bénite, France.
This case report presents an 82-year-old male initially diagnosed with classical mantle cell lymphoma (MCL) that progressed to the aggressive blastoid variant. The patient was initially treated with oral chemotherapy (PEP-C), followed by ibrutinib, but experienced disease progression with central nervous system (CNS) involvement and blastoid morphology. Despite subsequent intensive treatment, including high-dose cytarabine (Cytarabine), rituximab, and intrathecal methotrexate (Methotrexate), the patient's disease continued to advance, resulting in death.
View Article and Find Full Text PDFOutcome of patients with diffuse large B-cell lymphoma and testicular involvement - real world data.
Ann Hematol
October 2024
University Hospital and Faculty of Medicine, 4th Department of Internal Medicine- Hematology, Hradec Kralove, Czech Republic.
Patients with testicular lymphoma are at an increased risk of central nervous system (CNS) disease. Optimal strategy for CNS relapse prevention is unknown. We analyzed treatment strategies, cumulative incidence of CNS relapse and prognosis in 229 patients with diffuse large B-cell lymphoma (DLBCL) and testicular involvement: 157 primary testicular lymphomas (PTL) in clinical stages IE/IIE and 72 patients in advanced stages (T-DLBCL) IIIE/IV.
View Article and Find Full Text PDFEfficacy of thiotepa-conditioned autologous stem-cell transplantation as consolidation therapy for primary leptomeningeal malignant lymphoma: a case report and review of literature.
Ann Hematol
October 2024
Department of Hematology, Yokosuka Kyosai Hospital, 1-16 Yonegahamadori, Yokosuka, Kanagawa, Japan.
Article Synopsis
- Primary leptomeningeal malignant lymphoma (PLML) is a rare form of primary central nervous system lymphoma (PCNSL) with no established treatment due to its uniqueness.* -
- A case study of a 46-year-old male with PLML showed complete remission after treatment with a combination of chemotherapy (R-MPV and intrathecal agents) and autologous stem-cell transplantation (ASCT) using a thiotepa regimen.* -
- A literature review indicated that ASCT has been successfully used in three reported cases of PLML, suggesting it may be an effective consolidation therapy, but more research is necessary to develop standardized treatment guidelines.*
Comparison of various treatment modalities in patients with primary vitreoretinal lymphoma: A systematic review and meta-analysis.
Clin Exp Ophthalmol
September 2024
School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Background: This systematic review and meta-analysis investigated different treatment modalities' effect on the risk of central nervous system lymphoma progression, ocular disease relapse, systemic lymphoma development and overall survival in primary vitreoretinal lymphoma patients.
Methods: PubMed, EMBASE, Scopus and the Cochrane Library of clinical trials were searched from inception to April 21, 2024. Cohort, cross-sectional and case series studies were included.
Intrathecal IgG4 synthesis in IgG4 related spinal hypertrophic pachymeningitis: a case report.
Neurol Res Pract
August 2024
Department of Neurology with Experimental Neurology, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Article Synopsis
- Immunoglobulin G4 (IgG4) related hypertrophic pachymeningitis is a rare spinal cord condition marked by the infiltration of IgG4-producing plasma cells, leading to thickening of the spinal meninges.
- A case study focused on a 65-year-old woman who underwent cerebrospinal fluid (CSF) analysis, which revealed intrathecal IgG4 production and IgG4 positive plasma cells, helping in the diagnosis.
- The patient experienced clinical improvement after decompressive surgery and treatment with the immunosuppressive drug rituximab, emphasizing the importance of CSF analysis in diagnosing this condition.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!